scPharmaceuticals Inc SCPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SCPH is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.93
- Day Range
- $4.75–4.97
- 52-Week Range
- $4.63–12.75
- Bid/Ask
- $4.18 / $6.20
- Market Cap
- $175.22 Mil
- Volume/Avg
- 184,123 / 234,395
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.54
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 96
Comparables
Valuation
|
Metric
|
SCPH
|
ICVX
|
MRNS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.62 | 3.30 | 27.29 |
Price/Sales | 13.54 | — | 14.53 |
Price/Cash Flow | — | — | — |
Price/Earnings
SCPH
ICVX
MRNS
Financial Strength
|
Metric
|
SCPH
|
ICVX
|
MRNS
|
|---|---|---|---|
Quick Ratio | 6.13 | 17.59 | 3.79 |
Current Ratio | 7.08 | 18.06 | 4.07 |
Interest Coverage | −6.38 | — | −7.94 |
Quick Ratio
SCPH
ICVX
MRNS
Profitability
|
Metric
|
SCPH
|
ICVX
|
MRNS
|
|---|---|---|---|
Return on Assets (Normalized) | −47.33% | −29.30% | −59.45% |
Return on Equity (Normalized) | −89.93% | −31.87% | −195.80% |
Return on Invested Capital (Normalized) | −51.49% | −34.69% | −84.00% |
Return on Assets
SCPH
ICVX
MRNS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wstkdgfpjl | Htlgg | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xmnyyrh | Kfyxtk | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rpwvhmy | Qwjqfz | $98.6 Bil | |
MRNA
| Moderna Inc | Dyszmgc | Dnxj | $41.0 Bil | |
ARGX
| argenx SE ADR | Xtqcmdr | Tdpj | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Wymffgvq | Cbwt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mdnycps | Zyjwbyt | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yndwnbb | Mnfssd | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nyxqfstzgn | Ylcpw | $12.6 Bil | |
INCY
| Incyte Corp | Xbnxzsxh | Jykrmrj | $12.0 Bil |